Entyvio ^*

Entyvio® (vedolizumab) is a humanized monoclonal antibody approved for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease. It is designed to target the α4β7 integrin, a key molecule involved in directing inflammatory immune cells to the gastrointestinal tract. By specifically interfering with this pathway, Entyvio helps control chronic intestinal inflammation associated with inflammatory bowel disease (IBD). Unlike broader immunosuppressive biologics, Entyvio is gut-selective, meaning its mechanism of action is largely confined to the gastrointestinal system. This selectivity allows Entyvio to effectively reduce symptoms such as diarrhea, abdominal pain, and rectal bleeding while minimizing systemic immune effects. As a result, it has a differentiated safety profile compared with non-selective biologic therapies. Entyvio is administered as an intravenous infusion and is used both for induction and maintenance of remission in eligible patients. It is often prescribed for individuals who have had an inadequate response or intolerance to conventional therapies or other biologic agents. Manufactured by Takeda, Entyvio has become an established treatment option in the long-term management of inflammatory bowel disease.